1001 related articles for article (PubMed ID: 15066127)
1. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
2. Drugs for men and women - how important is gender as a risk factor for TdP?
Coker SJ
Pharmacol Ther; 2008 Aug; 119(2):186-94. PubMed ID: 18472167
[TBL] [Abstract][Full Text] [Related]
3. Gender differences in autonomic modulation of ventricular repolarization in humans.
Nakagawa M; Ooie T; Ou B; Ichinose M; Takahashi N; Hara M; Yonemochi H; Saikawa T
J Cardiovasc Electrophysiol; 2005 Mar; 16(3):278-84. PubMed ID: 15817086
[TBL] [Abstract][Full Text] [Related]
4. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human.
Cheng J
Fundam Clin Pharmacol; 2006 Feb; 20(1):1-8. PubMed ID: 16448390
[TBL] [Abstract][Full Text] [Related]
5. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
[TBL] [Abstract][Full Text] [Related]
6. Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology.
Jonsson MK; Vos MA; Duker G; Demolombe S; van Veen TA
Pharmacol Ther; 2010 Jul; 127(1):9-18. PubMed ID: 20462510
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in understanding sex differences in cardiac repolarization.
James AF; Choisy SC; Hancox JC
Prog Biophys Mol Biol; 2007 Jul; 94(3):265-319. PubMed ID: 15979693
[TBL] [Abstract][Full Text] [Related]
9. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
11. HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.
Singh M; Arora R; Jawad E
Am J Ther; 2010; 17(6):e193-201. PubMed ID: 19636247
[TBL] [Abstract][Full Text] [Related]
12. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
13. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
14. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation.
Di Diego JM; Belardinelli L; Antzelevitch C
Circulation; 2003 Aug; 108(8):1027-33. PubMed ID: 12912819
[TBL] [Abstract][Full Text] [Related]
15. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
[TBL] [Abstract][Full Text] [Related]
16. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
17. Greater quinidine-induced QTc interval prolongation in women.
Benton RE; Sale M; Flockhart DA; Woosley RL
Clin Pharmacol Ther; 2000 Apr; 67(4):413-8. PubMed ID: 10801251
[TBL] [Abstract][Full Text] [Related]
18. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
19. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
Thomsen MB; Verduyn SC; Stengl M; Beekman JD; de Pater G; van Opstal J; Volders PG; Vos MA
Circulation; 2004 Oct; 110(16):2453-9. PubMed ID: 15477402
[TBL] [Abstract][Full Text] [Related]
20. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
